Vtv Theraptcs Cl A (VTVT) Stock Price, Quote & News

Company Profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a lic...

Industry: Biotechnology

Sector: Healthcare

Phone: 336 841 0300

Fax: 336 841 0310

Website: vtvtherapeutics.com

Address:

3980 Premier Drive, Suite 310, High Point, United States

GDS_investing Jul. 2 at 6:42 PM

$RFL There is accumulation of stock throughout the trading day. long and strong $RFL and $VTVT

0 · Reply

dcajic2 Jul. 2 at 1:34 PM

$VTVT no volume. Would like to short a few again. Could be awhile before any data break

0 · Reply

GDS_investing Jul. 2 at 11:01 AM

$RFL 5 year chart looks crazy We are currently in the 3.19 breakout phase, next target 5.90 and $10 area. then there is an open gap that needs to be closed in the $30 area. LONG and strong $RFL and $VTVT

1 · Reply

dcajic2 Jul. 1 at 10:17 PM

$VTVT good volume Yet the stock is down close to 7%. Anorher good short day. One needs to be reminded that this management is so very slow with any news. Second half of the year could literally be December with this company.

0 · Reply

dcajic2 Jul. 1 at 3:38 PM

$VTVT what is the reason why one would consider it a buy today. Some Volume today but price is down 4%. Don’t you think if it was truly bullish any volume would be towards the upside?

0 · Reply

dcajic2 Jul. 1 at 3:36 PM

$VTVT another one of my shorts is working out. Each day without news likely people will walk back the price.

0 · Reply

GDS_investing Jul. 1 at 3:21 PM

$RFL awesome call here glta my followers long $RFL and $VTVT

1 · Reply

GDS_investing Jun. 30 at 5:54 PM

$VTVT nice volume today very low float watch $CELZ $JEM

0 · Reply

dcajic2 Jun. 30 at 5:50 PM

$VTVT the stock may be a buy but I have been following this stock for so many years now and management is really slow with information. Go back and look at trading action. It goes higher and then goes back much lower. I am shorting many shares because I am going with past experience. This company needs to show great data and it could be many many months away.

0 · Reply

GDS_investing Jun. 30 at 3:19 PM

$VTVT new BUY UPGRADES 67 !! 70%+ : " Rodman & Renshaw initiates vTv Therapeutics stock with buy rating" nvesting.com - Rodman & Renshaw initiated coverage on vTv Therapeutics Inc. (NASDAQ:VTVT) with a buy rating and set a price target of $67.00 $VTVT https://www.investing.com/news/analyst-ratings/rodman--renshaw-initiates-vtv-therapeutics-stock-with-buy-rating-93CH-4767908 (watch $CELZ $JEM )

0 · Reply

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-06-30T12:26:19.000Z - 4 days ago

vTv Therapeutics initiated with a Buy at Rodman & Renshaw

Jun 26, 2026, 11:00 AM EDT - 8 days ago

vTv Therapeutics Transcript: AGM 2026

Jun 10, 2026, 8:00 AM EDT - 24 days ago

vTv Therapeutics Proxy statement: Proxy filing

Jun 3, 2026, 5:05 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:05 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:04 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:04 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:03 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:03 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:03 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:02 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:02 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:02 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:01 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:01 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 1, 2026, 11:02 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 1, 2026, 11:02 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 1, 2026, 11:01 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 1, 2026, 10:58 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

Jun 1, 2026, 10:56 AM EDT - 4 weeks ago

vTv Therapeutics Earnings release

2026-05-13T20:13:15.000Z - 7 weeks ago

vTv Therapeutics reports Q1 EPS $1.65, consensus 21c

May 13, 2026, 4:01 PM EDT - 7 weeks ago

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026, 8:00 AM EDT - 2 months ago

vTv Therapeutics to Participate in Upcoming May Investor Conferences

Mar 23, 2026, 2:00 PM EDT - 3 months ago

vTv Therapeutics Transcript: 38th Annual Roth Conference

Mar 16, 2026, 8:00 AM EDT - 3 months ago

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

2026-03-12T10:46:05.000Z - 4 months ago

vTv Therapeutics initiated with an Outperform at Evercore ISI

2026-03-11T11:11:56.000Z - 4 months ago

vTv Therapeutics price target raised to $55 from $35 at Alliance Global

2026-03-10T20:11:02.000Z - 4 months ago

vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09)

Mar 10, 2026, 4:01 PM EDT - 4 months ago

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 3, 2026, 9:50 AM EST - 4 months ago

vTv Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 13, 2026, 8:00 AM EST - 5 months ago

vTv Therapeutics to Participate in Upcoming Investor Conferences

2026-02-02T13:15:17.000Z - 5 months ago

vTv Therapeutics expanded its license agreement with Newsoara Biopharma

Feb 2, 2026, 8:00 AM EST - 5 months ago

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

2026-01-27T12:25:32.000Z - 5 months ago

vTv Therapeutics price target raised to $49 from $40 at BTIG

2026-01-22T21:11:50.000Z - 5 months ago

vTv Therapeutics initiated with a Buy at Roth Capital

2026-01-05T10:50:07.000Z - 6 months ago

vTv Therapeutics initiated with a Buy at TD Cowen

2025-12-19T13:20:18.000Z - 7 months ago

vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright

2025-12-18T21:10:54.000Z - 7 months ago

vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi

Dec 18, 2025, 4:05 PM EST - 7 months ago

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

2025-11-18T21:20:58.000Z - 8 months ago

vTv Therapeutics initiated with a Buy at BTIG

2025-11-06T22:30:59.000Z - 8 months ago

vTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)

Nov 6, 2025, 4:15 PM EST - 8 months ago

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-05T14:42:37.000Z - 8 months ago

vTv Therapeutics trading resumes

2025-11-05T14:36:57.000Z - 8 months ago

vTv Therapeutics trading halted, volatility trading pause

2025-10-09T12:11:55.000Z - 9 months ago

vTv Therapeutics announces three appointments to Scientific Advisory Board

Oct 9, 2025, 8:00 AM EDT - 9 months ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

2025-10-03T20:45:20.000Z - 9 months ago

vTv Therapeutics files to sell 15.88M shares of Class A common stock for holders

2025-09-17T14:00:38.000Z - 10 months ago

vTv Therapeutics trading resumes

2025-09-17T13:55:25.000Z - 10 months ago

vTv Therapeutics trading halted, volatility trading pause

Sep 15, 2025, 8:00 AM EDT - 10 months ago

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 3, 2025, 4:57 PM EDT - 10 months ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 10 months ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

2025-09-02T12:30:44.000Z - 10 months ago

vTv Therapeutics announces $80M private placement

Sep 2, 2025, 8:00 AM EDT - 10 months ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Aug 12, 2025, 4:15 PM EDT - 11 months ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 8:00 AM EDT - 11 months ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 7, 2025, 8:00 AM EDT - 11 months ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Jun 11, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

May 19, 2025, 9:00 AM EDT - 1 year ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 15, 2025, 4:01 PM EDT - 1 year ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 12:00 PM EDT - 1 year ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Mar 20, 2025, 5:35 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 17, 2025, 8:30 AM EDT - 1 year ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Dec 9, 2024, 7:33 AM EST - 1 year ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 2, 2024, 4:05 PM EST - 1 year ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Aug 8, 2024, 4:15 PM EDT - 2 years ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Jul 26, 2024, 4:05 PM EDT - 2 years ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jun 24, 2024, 4:05 PM EDT - 2 years ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

May 28, 2024, 8:00 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 9, 2024, 4:51 PM EDT - 2 years ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

Mar 19, 2024, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 13, 2024, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 4, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 1, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Feb 28, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 22, 2024, 4:00 PM EST - 2 years ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Nov 9, 2023, 4:30 PM EST - 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2023, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 2, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 1, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Sep 27, 2023, 8:30 AM EDT - 3 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

$Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer$

Sep 26, 2023, 8:30 AM EDT - 3 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 18, 2023, 8:30 AM EDT - 3 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Aug 11, 2023, 4:30 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 10, 2023, 8:33 AM EDT - 3 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Jun 16, 2023, 8:00 AM EDT - 3 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 15, 2023, 7:33 AM EDT - 3 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

May 24, 2023, 9:00 AM EDT - 3 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 11, 2023, 4:15 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Apr 20, 2023, 8:00 AM EDT - 3 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

GDS_investing Jul. 2 at 6:42 PM

$RFL There is accumulation of stock throughout the trading day. long and strong $RFL and $VTVT

0 · Reply

dcajic2 Jul. 2 at 1:34 PM

$VTVT no volume. Would like to short a few again. Could be awhile before any data break

0 · Reply

GDS_investing Jul. 2 at 11:01 AM

1 · Reply

dcajic2 Jul. 1 at 10:17 PM

0 · Reply

dcajic2 Jul. 1 at 3:38 PM

$VTVT what is the reason why one would consider it a buy today. Some Volume today but price is down 4%. Don’t you think if it was truly bullish any volume would be towards the upside?

0 · Reply

dcajic2 Jul. 1 at 3:36 PM

$VTVT another one of my shorts is working out. Each day without news likely people will walk back the price.

0 · Reply

GDS_investing Jul. 1 at 3:21 PM

$RFL awesome call here glta my followers long $RFL and $VTVT

1 · Reply

GDS_investing Jun. 30 at 5:54 PM

$VTVT nice volume today very low float watch $CELZ $JEM

0 · Reply

dcajic2 Jun. 30 at 5:50 PM

0 · Reply

GDS_investing Jun. 30 at 3:19 PM

0 · Reply

notreload_ai Jun. 30 at 3:00 PM

$MKSI $RKT $AVNW $AIB $VTVT -- THE WSJ

0 · Reply

dcajic2 Jun. 30 at 2:20 PM

$VTVT Trying to ge tad many shorts as possible. Reality land. There isn’t even in dictations that the trials are doing well. It could literally be months before we know anything.

0 · Reply

dcajic2 Jun. 30 at 1:57 PM

$VTVT What exactly makes this stock a guy at this moment in time? I still feel like another short is in the cards. This management team does not put out very much information. The only information is May get data in second half of the year. This company is super slow with news. Second half of the year news could essentially be in December.

0 · Reply

G101SPM Jun. 30 at 12:38 PM

$VTVT $36.38 ask. BUY/NEW LONG POSITION carries SPM 87.35 tag to $70.00 in long term

0 · Reply

GDS_investing Jun. 29 at 7:45 PM

$RFL great call here glta my followers add $VTVT

0 · Reply

dcajic2 Jun. 29 at 7:08 PM

$VTVT Still think too early to consider the company to be long. Shorting again. It could literally be many months before any real news. Too me it is nothing more than a bet news will be dropped soon but anyone who has followed this company for a significant period of time knows they are one of the worst communicator

0 · Reply

GDS_investing Jun. 29 at 6:02 PM

$VTVT nice volume so far very low float on the move. $RFL im love on it long

0 · Reply

GDS_investing Jun. 29 at 3:08 PM

$RFL yes. $VTVT yes all long

0 · Reply

dcajic2 Jun. 26 at 7:41 PM

$VTVT I was right again. Nothing more than a short. Not sure where volume comes from With this stock. Stock rises but always falls because no news and no real communication from management.

0 · Reply

dcajic2 Jun. 26 at 3:56 PM

$VTVT shorting a few more. Literally makes no sense how it’s bulli yet. If it was really bullish the volume would be sommixh higher and the stock would continue to go higher. Not bullish yet.

0 · Reply

dcajic2 Jun. 26 at 3:04 PM

$VTVT still like it as a short. Too early for it to be a long. Management barely speaks. No indication that data is coming shortly. Jus take a look at the last year of trading. Every single time you think it’s going higher it gets kicked lower.

0 · Reply

GDS_investing Jun. 26 at 2:18 PM

$VTVT on the nice breakout next targets 44 56 and 84 long $VTVT and $RFL

1 · Reply

Market Cap	139.44M
Revenue (ttm)	0.00
Net Income (ttm)	-26.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	61,000
Avg Vol	53,430
Day's Range	N/A - N/A
Shares Out	3.94M
Stochastic %K	39%
Beta	0.25
Analysts	Strong Sell
Price Target	$55.00